Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), continues to support genitourinary cancer research with the ...
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCLast year’s ...
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets ...
A new study may pave the way toward more personalized treatments for patients with high-risk bladder cancer, according to a study published in European Urology.
Stocktwits on MSN
IBRX stock jumps overnight after major FDA review win for Anktiva in bladder cancer
The FDA will review the expansion of Anktiva plus BCG to patients with papillary-only bladder cancer, with a final decision expected by Jan.6, 2027. ・The acceptance reversed last year’s FDA refusal-to ...
“There’s almost this disbelief that washes over you, like your brain can’t fully process what it’s being told," James “Jimi” ...
Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete response (CR) in ...
A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...
Bladder cancer happens when cells in the bladder start to grow out of control. These cells can form a tumor and, over time, ...
ImmunityBio, Inc. receives a Strong Buy rating, driven by ANKTIVA's compelling clinical data and major regulatory catalysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results